Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.

Autor: Eltelbanei MA; Senior Clinical Pharmacist in Hematology, Oncology, and Stem Cell Transplantation at International Medical Center (IMC) Hospital, Clinical pharmacy & pharmacy practice master candidate at Faculty of pharmacy, Damanhour University, Cairo, Egypt. mohamedalieltelbaney@gmail.com., El-Bassiouny NA; Clinical Pharmacy & Pharmacy Practice Department, Faculty of Pharmacy, Damanhour University, Damanhour, 22514, Egypt., Abdalla MS; Hematology& BMT Department at International Medical Center (IMC) Hospital, Cairo, Egypt., Khalaf M; Consultant of Hematology & BMT Department at Maadi Military Hospital, Cairo, Egypt. mhkhalaf@hotmail.com., Werida RH; Clinical Pharmacy & Pharmacy Practice Department, Faculty of Pharmacy, Damanhour University, Damanhour, 22514, Egypt. rehabwrieda@pharm.dmu.edu.eg.

Publikováno v: BMC cancer [BMC Cancer] 2024 Aug 13; Vol. 24 (1), pp. 1002. Date of Electronic Publication: 2024 Aug 13.